Every parliamentary written question tabled by Gordon McKee this session, with the full answer and department. See how every department answers, or back to the MP page.
Showing 1–11 of 11 · Department of Health and Social Care
What formal mechanisms are in place to ensure that the views of patients, families and brain cancer patient advocacy organisations are reflected in the work of the National Clinical Lead for Rare Cancers, the Rare Cancer Speciality Lead and the National Cancer Board; and how those bodies will be expected to respond to, and report on, the concerns raised through those mechanisms.
Awaiting answer.
What measurable improvements in (a) workforce capacity, (b) research activity, (c) clinical trial access, (d) speed of diagnosis and (e) patient outcomes are expected as a result of the work of the National Clinical Lead for Rare Cancers, the Rare Cancer Specialty Lead and the National Cancer Board; how those improvements are expected to build on previous arrangements; by what dates they are expected to be achieved; and what arrangements are in place to monitor progress and ensure accountability.
Awaiting answer.
What key performance indicators and outcome measures will be used to assess the effectiveness of the National Cancer Board; who will be responsible for overseeing delivery of those outcomes; where information on the Board's performance will be published; and how the interests of brain cancer patients will be represented in the Board's decision-making.
Awaiting answer.
Whether his department will consider the appointment of a specific National Clinical Lead for Brain Cancers.
Awaiting answer.
Whether the (a) National Clinical Lead for Rare Cancers and (b) Rare Cancer Specialty Lead have been appointed; if so, on what date, and against which National Cancer Plan commitments they will be assessed; and if not, when appointments are expected to be made and who is currently undertaking those functions.
Awaiting answer.
Which recommendations relating to the cancer workforce from previous workforce reviews, task and finish groups, and National Cancer Board workstreams remain outstanding; what assessment has been made of the impact of those outstanding recommendations on brain cancer patients; and how the National Clinical Lead for Rare Cancers, the Rare Cancer Speciality Lead and the National Cancer Board will support their implementation.
Awaiting answer.
By what date liquid biopsy technologies will be routinely available for brain tumour patients across the NHS; how many additional patients are expected to gain access to targeted or repurposed treatments as a result; what barriers currently prevent access to such treatments where the same mutation is already treated in another cancer type; and who will be responsible for working to remove those barriers.
Awaiting answer.
What discussions he has had with the devolved administrations on developing a coordinated UK approach to addressing shortages in the NHS workforce in key specialties.
Awaiting answer.
What steps the Department is taking with the devolved administrations to increase the number of patients able to participate in commercial clinical trials across the UK.
Awaiting answer.
What steps the Department is taking to improve interoperability between rare-disease registries and genomic-data systems across the UK.
Awaiting answer.
How many cybersecurity vulnerabilities affecting medical devices have been reported to the Medicines and Healthcare products Regulatory Agency in each of the last three years.
Awaiting answer.